Skip to main content

Table 1 Patients’ characteristics according to the presence or absence of atherogenic dyslipidemia

From: Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study

 

Total

n = 1080

No atherogenic dyslipidemia

n = 1020

Atherogenic dyslipidemia

n = 60

p

Clinical characteristics

 Age, years

61.6 ± 9.0

61.7 ± 9.1

59.7 ± 8.2

0.09

 Gender, male/female

614/466

577/443

37/23

0.44

 Body mass index, kg/m2

30.2 ± 5.9

30.2 ± 6.0

31.1 ± 4.9

0.23

 Waist circumference, cm

104 ± 13

104 ± 13

107 ± 10

0.37

Diabetes

 Diabetes duration, years

13.8 ± 8.5

13.9 ± 8.6

11.8 ± 6.9

0.07

 HbA1c, %

8.5 ± 1.8

8.4 ± 1.8

8.6 ± 2.0

0.42

 HbA1c, mmol/mol

69 ± 6

68 ± 6

70 ± 7

0.42

 Retinopathy, %

357 (34.2)

341 (34.7)

16 (27.1)

0.24

 Nephropathy, %

406 (57.3)

383 (57.5)

23 (53.5)

0.61

 Peripheral arterial occlusive disease, %

119 (11.3)

110 (11.1)

9 (15.8)

0.27

Additional cardiovascular risk factors

 Family history of premature CAD, %

137 (13.0)

126 (12.7)

11 (19.0)

0.16

 Hypertension, %

402 (76.3)

376 (76.3)

26 (76.5)

0.98

 Lipid parameters

  Total cholesterol, mmol/L

4.5 ± 0.7

4.5 ± 0.7

4.7 ± 0.7

<0.05

  HDL cholesterol, mmol/L

1.3 ± 0.5

1.3 ± 0.5

0.8 ± 0.1

<0.0001

  Triglycerides, mmol/L

1.7 ± 1.0

1.6 ± 0.8

3.4 ± 1.1

<0.0001

  LDL cholesterol, mmol/L

2.4 ± 0.6

2.4 ± 0.6

2.4 ± 0.6

0.27

  Non HDL cholesterol, mmol/L

3.2 ± 0.7

3.1 ± 0.7

3.9 ± 0.7

<0.0001

  Apoprotein A1, g/L

1.47 ± 0.74

1.49 ± 0.28

1.10 ± 0.12

<0.0001

  Apoprotein B, g/L

0.89 ± 0.18

0.89 ± 0.18

1.10 ± 0.12

0.06

  Fibrate treatment, %

96 (9.1)

87 (8.7)

9 (15.8)

0.09

  Statin treatment, %

438 (41.4)

415 (41.5)

23 (40.4)

0.87

 Smoking, %

245 (22.8)

226 (22.3)

19 (32.2)

0.08

  1. Data are n (%) or mean ± SD
  2. CAD coronary artery disease